Search results for "Gastric"

showing 10 items of 536 documents

The Expression and Prognostic Significance of VEGF and CXCR4 in Gastric Cancer: Correlation with Angiogenesis, Lymphangiogenesis and Progression

2022

The cellular response to hypoxia includes the expression of hypoxia-inducible factor-1 (HIF-1) and its target genes: vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4). The aim of this study was to investigate the expression and prognostic significance of VEGF and CXCR4, which are responsible for angiogenesis and progression in gastric cancer. Twenty-eight gastric cancer patients were analyzed. The mRNA expression was examined in primary tumors and corresponding normal gastric mucosa by RT-PCR. The protein level was examined by immunohistochemistry staining. The high expression of VEGF and CXCR4 was found in 71.0 and 64.0% of tumors, respectively. The mean levels…

Microbiology (medical)gastric cancer; VEGF; CXCR4; angiogenesis; lymphangiogenesis; lymph node metastasesGeneral MedicineMolecular BiologyMicrobiologyCurrent Issues in Molecular Biology
researchProduct

Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma

2019

Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effecti…

0301 basic medicineOncologymedicine.medical_specialtyEsophageal NeoplasmsTumour heterogeneityReceptor ErbB-2DiseaseDrug resistanceAdenocarcinomaGastroesophageal Junction AdenocarcinomaGenetic Heterogeneity03 medical and health sciences0302 clinical medicineStomach NeoplasmsTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPrecision Medicineskin and connective tissue diseasesGastroesophageal adenocarcinomabusiness.industryGene AmplificationHematologyPrognosisPrecision medicineProgression-Free SurvivalBlockade030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisEsophagogastric Junctionbusinessmedicine.drugAnnals of Oncology
researchProduct

Perioperative nonspecific histamine release : a new classification by aetiological mechanisms and evaluation of their clinical relevance

1993

As a consequence of the performance of a randomized controlled clinical trial on perioperative histamine release and cardiovascular and respiratory disturbances, several types of increases in plasma histamine had to be distinguished instead of only two which existed at the beginning of the study: drug-induced allergic and pseudoallergic reactions. First of all, the new classification by aetiology (clinical epidemiology) was derived from a meta-analysis (secondary analysis) of the most recent literature. According to that histamine release in the perioperative period has several, different causes and is involved in several, different disease manifestations. A clear distinction (classificatio…

AdultMaleHistamine ReleaseDrug HypersensitivityIntraoperative Periodchemistry.chemical_compoundHumansMedicineAnesthesiaClinical significanceProspective StudiesAgedAnestheticsNeurosecretionbusiness.industryGeneral MedicinePerioperativeMiddle AgedPathophysiologyAnalgesics OpioidClinical trialAnesthesiology and Pain MedicinechemistryAnesthesiaEtiologyGastric acidFemalePremedicationNeuromuscular Blocking AgentsbusinessHistamineHistamineAnnales Françaises d'Anesthésie et de Réanimation
researchProduct

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress

2020

Gastroesophageal adenocarcinoma (GEA) represents a heterogeneous disease and, when diagnosed as locally advanced or metastatic, it is characterized by poor prognosis. During the last few years, several molecular classifications have been proposed to try to personalize treatment for those patients diagnosed with advanced disease. Nevertheless, despite the great effort, precision medicine is still far from being a reality. The improvement in the molecular analysis due to the application of high throughput technologies based on DNA and RNA sequencing has opened a novel scenario leading to the personalization of treatment. The possibility to target epidermal growth factor receptor (HER)2, Claud…

Oncologymedicine.medical_specialtymedicine.medical_treatmentprecision medicinePopulationlcsh:MedicineReviewDisease03 medical and health sciences0302 clinical medicineInternal medicinemedicineEpidermal growth factor receptoreducationadvanced gastric cancer030304 developmental biology0303 health scienceseducation.field_of_studyGastroesophageal adenocarcinomabiologybusiness.industrylcsh:RGeneral MedicineImmunotherapyAdvanced gastric cancerPrecision medicineAdvanced gastric cancer; New drug development; Precision medicineFibroblast growth factor receptor030220 oncology & carcinogenesisbiology.proteinnew drug developmentbusinessJournal of Clinical Medicine
researchProduct

Early miR-223 Upregulation in Gastroesophageal Carcinogenesis

2017

Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Res…

0301 basic medicineMalePathologyEsophageal NeoplasmsAtrophic gastritisCarcinogenesisPreneoplastic lesionsBarrett carcinogenesisGastroenterology0302 clinical medicineEarly Detection of CancerIn Situ HybridizationBarrett carcinogenesis; Gastric adenocarcinoma; Preneoplastic lesions; microRNA; Adenocarcinoma; Aged; Barrett Esophagus; Biomarkers Tumor; Carcinogenesis; Early Detection of Cancer; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; In Situ Hybridization; Male; MicroRNAs; Middle Aged; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Up-RegulationTumormedicine.diagnostic_testmicroRNAReverse Transcriptase Polymerase Chain ReactionBarrett carcinogenesiIntestinal metaplasiaGeneral MedicineMiddle AgedUp-RegulationReverse transcription polymerase chain reactionmedicine.anatomical_structure030220 oncology & carcinogenesisAdenocarcinomaBiomarker (medicine)FemaleEsophagogastric Junctionmedicine.medical_specialty2734BiologyAdenocarcinoma03 medical and health sciencesBarrett EsophagusStomach NeoplasmsInternal medicineBiopsyBiomarkers TumormedicineHumansEsophagusAgedRetrospective StudiesGastric adenocarcinomaCancermedicine.diseasedigestive system diseasesBarrett carcinogenesis; Gastric adenocarcinoma; microRNA; Preneoplastic lesions; Adenocarcinoma; Aged; Barrett Esophagus; Biomarkers Tumor; Carcinogenesis; Early Detection of Cancer; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; In Situ Hybridization; Male; MicroRNAs; Middle Aged; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Up-Regulation; 2734MicroRNAs030104 developmental biologyBiomarkers
researchProduct

Polymorphisms of microRNA target genes

2016

AIM To evaluate associations between miRNA target genes IL12B, INSR, CCND1 and IL10 polymorphisms and gastric cancer (GC) in European population. METHODS Gene polymorphisms were analyzed in 508 controls and 474 GC patients from 3 tertiary centers in Germany, Lithuania and Latvia. Controls were patients from the out-patient departments, who were referred for upper endoscopy because of dyspeptic symptoms and had no history of previous malignancy. Gastric cancer (GC) patients had histopathological verification of gastric adenocarcinoma. Genomic DNA was extracted using salting out method from peripheral blood mononuclear cells. IL12B T>G (rs1368439), INSR T>C (rs1051690), CCND1 A>C (rs7177) and…

AdultMaleGenotypeInterleukin-12 Subunit p40LithuaniaMiddle AgedCase Control StudyLatviaPolymorphism Single NucleotideSingle-nucleotide polymorphismsReceptor InsulinInterleukin-10Antigens CDStomach NeoplasmsCase-Control StudiesGermanyLeukocytes MononuclearHumansRegression AnalysisCyclin D1FemaleTarget genesGastric cancerAgedmiRNAWorld journal of gastroenterology
researchProduct

Implementation of gastric cancer screening - the global experience.

2014

Gastric cancer (GC) is still an important global healthcare problem, and in absolute figures it is going to remain at the present level in foreseeable future. In general, survival of patients with GC is poor mainly due to advanced-stage diagnosis. Early-stage GC can be cured by endoscopic resection or less invasive surgical treatment. Unfortunately, there is no appropriate screening strategy available for global application. This article provides a description of established national and regional GC screening programs and the screening modalities used. This review also summarizes current approaches to develop cancer-screening biomarkers. Although candidates with initial promising results ha…

medicine.medical_specialtyModalitiesbusiness.industryGastroenterologyCancermedicine.diseaseGlobal HealthArticleSurgeryStomach NeoplasmsHealth caremedicineBiomarkers TumorFatal diseaseGastric cancer screeningBiomarker (medicine)HumansEndoscopic resectionIntensive care medicinebusinessSurgical treatmentEarly Detection of CancerBest practiceresearch. Clinical gastroenterology
researchProduct

The Effects of Sodium Nitroprusside-Induced Hypotension on Splanchnic Perfusion and Hepatocellular Integrity

1999

UNLABELLED The purpose of our study was to investigate the effects of sodium nitroprusside-induced hypotension on splanchnic perfusion and hepatocellular integrity. Thirty patients undergoing radical prostatectomy were allocated randomly to a sodium nitroprusside (SNP) or control group (control). Regional pco2 was measured using gastric tonometry, and the regional to arterial difference in partial pressure of CO2 and intramucosal pH were calculated. The cytosolic liver enzyme alpha-glutathione S-transferase and standard liver enzyme markers (alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyltransferase) were also measured. Mean arterial pressure in the SNP group was 50…

MaleNitroprussideMean arterial pressuremedicine.medical_specialtyPartial PressureVasodilator AgentsUrologyHemodynamicsBlood PressurepCO2medicineHumansSplanchnic CirculationGastric tonometryAntihypertensive AgentsGlutathione TransferaseProstatectomybusiness.industryLiver DiseasesCarbon DioxideMiddle AgedIsoenzymesOxygenAnesthesiology and Pain MedicineLiverAnesthesiaSodium nitroprussideLiver functionChemical and Drug Induced Liver InjuryHypotensionSplanchnicbusinessPerfusionBiomarkersmedicine.drugAnesthesia & Analgesia
researchProduct

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Ju…

2017

Abstract Purpose: Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte–associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase II study evaluated the safety and efficacy of ipilimumab monotherapy versus best supportive care (BSC) among patients with advanced/metastatic gastric or gastroesophageal junction cancer who achieved at least stable disease with first-line chemotherapy. Experimental Design: Eligible patients were randomized to ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years, or BSC, which could include continuation of fluoropyrimidine until progression or toxicity. The prim…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsPhases of clinical researchIpilimumabDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansAdverse effectAgedbusiness.industryCancerMiddle AgedInterim analysismedicine.diseaseIpilimumabSurgeryClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleEsophagogastric Junctionbusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Effects of endotoxin on neurally-mediated gastric acid secretion in the rat.

1998

Abstract The effects of a peripheral administration of E. coli endotoxin on neurally-mediated gastric acid secretion and the role of endogenous opioids or PAF receptors in endotoxin effects have been evaluated in the continuously perfused stomach of the anaesthetized rat. Gastric acid secretion stimulated by distension (20 cm H2O) was reduced dose-dependently by single intravenous bolus injection of endotoxin (0.1–10 μg kg−1). Doses of 5 μg kg−1 induced a peak reduction of distension-stimulated acid output and significantly reduced the secretory response induced by an intravenous bolus of 2-deoxy-d-glucose (150 mg kg−1). This dose of endotoxin did not significantly modify mean systemic arte…

Malemedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceBlood PressureReceptors Cell Surface(+)-NaloxonePlatelet Membrane GlycoproteinsDistensionDeoxyglucoseReceptors G-Protein-CoupledGastric AcidOpioid receptorInternal medicinemedicineEscherichia coliAnimalsRats WistarEndogenous opioidPharmacologyDose-Response Relationship Drugbusiness.industryNaloxoneGastric distensionStomachAntagonistAzepinesTriazolesReceptor antagonistRatsEndotoxinsEndocrinologyOpioid PeptidesReceptors OpioidGastric acidFemalemedicine.symptombusinessPlatelet Aggregation InhibitorsThe Journal of pharmacy and pharmacology
researchProduct